CD47 and neoplasm: This novel combination immunotherapy of NDV and CD47 ICIs leverages the induction of a proinflammatory tumor microenvironment and recruitment of anti-tumor immune cells by NDV, with increased phagocytosis and antigen presentation mediated by CD47 blockade.